Sculpta is a science-first biotech startup developing RNA-based neurotherapeutics to modulate disease-associated biological pathways with higher precision and efficacy. Our CEO is a former Stanford University Assistant Professor and physician-scientist (MD/PhD) with publications in Nature, Cell, Science, etc. Our team includes accomplished scientists with expertise in RNA biology, brain organoids, transcriptomics, and machine learning. Backed by VCs with an oversubscribed pre-seed round in March 2025, we’re building a platform that will drive translational discovery and make a difference in brain health for all.
Company Details
- Employees
- 5
- Address
- 135 Mississippi St, San Francisco,california 94107,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- in RNA biology.
- HQ
- San Francisco, California
Sculpta Bio Questions
Sculpta Bio's LinkedIn profile is https://www.linkedin.com/company/sculptabio
Sculpta Bio has
5 employees.
View email and phone details for 5
employees at Sculpta Bio.
Sculpta Bio's industry is
Biotechnology Research
Sculpta Bio's top competitors are
Harken Research,
Dinamo Biotechnologies,
Neurocore Llc,
Viltis,
Anthrogen (Yc S24),
Ardence Consulting,
Adaptyx Biosciences,
Huminly,
Synlico Inc.,
Acrobat Genomics.
Sculpta Bio's categories are Biotechnology Research
